A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer
A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer
复制标题
循环非编码 RNA 组合作为非小细胞肺癌的早期检测预测因子
DOI：
10.1016/j.lfs.2016.03.002
复制
发表时间：
2016-04-15
期刊：
影响因子：
6.1
通讯作者：
Huang, Chang-zhi
中科院分区：
文献类型：
--
作者：
Peng, Hua;Wang, Jia;Huang, Chang-zhi
目的：早期非小细胞肺癌（NSCLC）的诊断普遍较差，由于缺乏方便和非侵入性的工具。microRNAs（miRNAs）和长链非编码RNA转移相关的肺腺癌转录本1（MALAT 1）是非编码RNA，作为NSCLC肿瘤诊断标志物受到越来越多的关注。我们通过定量逆转录聚合酶链反应测试了11种候选miRNAs和MALAT 1在训练组（36个NSCLC与36个对照组）中的表达。在第二个验证样本集中测试和验证血清非编码RNA组的诊断效率（120例NSCLC和71例对照）的受试者工作特征（ROC）曲线分析。在训练集中，四种非编码RNA的表达miR-1254、miR-485- 5 p、miR-574- 5 p和MALAT 1在NSCLC患者和健康对照组中的表达差异有统计学意义。风险评分分析显示，四种非编码RNA组可以区分NSCLC患者样本和对照样本。ROC曲线结果显示曲线下面积（AUC）为0.861（95%置信区间（CI）0.771-0.952）和0.844（95%CI 0.778 -0.910）。显著性：四种非编码RNA风险评分也与NSCLC进展相关，其对I/II/III期的诊断效率相对较高。总之，这些数据表明四种非编码RNA组可以作为早期NSCLC诊断的方便工具。(C)2016 Elsevier Inc. All rights reserved.
Aims: Early non-small cell lung cancer (NSCLC) diagnosis is generally poor due to the lack of convenient and non-invasive tools. MicroRNAs (miRNAs) and the long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) are non-coding RNAs, that have attracted increased attention for their use as NSCLC tumor diagnostic markers.Main methods: We constructed a serum miRNA and MALAT1 non-coding RNA panel and tested its diagnostic performance as an NSCLC biomarker. We tested the expression of 11 candidate miRNAs and MALAT1 in a training set (36 NSCLCs vs. 36 controls) by quantitative reverse transcription polymerase chain reactions. The serum non-coding RNA panel's diagnostic efficiency was tested and validated in a second validation sample set (120 NSCLCs and 71 controls) by receiver operating characteristic (ROC) curve analyses.Key findings: In the training set, the expression of the four non-coding RNAs (miR-1254, miR-485-5p, miR-574-5p, and MALAT1) was obviously different between the NSCLC patients and healthy controls. Risk score analysis revealed that the four non-coding RNA panel can distinguish NSCLC patient samples from controls. The ROC curve results revealed areas under the curves (AUCs) of 0.861 (95% confidence interval (CI) 0.771-0.952) and 0.844 (95% CI0.778-0.910) for the training set and validation set, respectively.Significance: The four non-coding RNA risk scores were also associated with NSCLC progression, and its diagnostic efficiency was relatively high for stages I/II/III. In conclusion, these data indicate that the four non-coding RNA panel can serve as a convenient tool for early NSCLC diagnosis. (C) 2016 Elsevier Inc. All rights reserved.